SynAct Pharma appoints Patrik Renblad as CFO
SynAct Pharma AB (“SynAct”) today announced that Patrik Renblad has been appointed Chief Financial Officer (CFO). Patrik Renblad joined the group in August 2021 as Vice President Finance and has since led the preparation for the upcoming listing of the Company at Nasdaq Main Market in Stockholm. Henrik Stage, who has been CFO of SynAct since 2016, will continue to support the Company as Special Advisor to the CEO.
Patrik Renblad joined SynAct Pharma as Vice President Finance in August 2021 and has more than 20 years of experience from different roles in large and mid-sized pharmaceutical companies, most recent LEO Pharma. He has worked in the interface between finance and business in all parts of the pharma value chain, from early Research and Development through Manufacturing to Commercial and importantly, Business Development.
“I am proud and honored of the appointment as CFO of SynAct Pharma. It is a great company with fantastic opportunities ahead. I am committed to growing the shareholder value and my first and top priority for 2022 will be to take the company through the IPO process towards a listing on Nasdaq Main Market”, said Patrik Renblad, CFO of SynAct.
Henrik Stage, who has been CFO since 2016, remains affiliated to SynAct as a Special Advisor to the CEO until the Company has been approved for and initiated trading on Nasdaq Main Market in Stockholm.
“I am confident that we have found a strong CFO who is devoted to SynAct. Patrik fits very well in the organization and will bring value to the company and our shareholders. I would also like express my sincere gratitude for Henrik Stage and his contribution to SynAct. Henrik was instrumental in taking the Company public in 2016, has led several financing rounds, and helped bring SynAct to where it is today”, said Jeppe Øvlesen, CEO.
The information was submitted, through the agency of the contact person below, for publication on January 7, 2022
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: +45 28 44 75 67
Mail: joo@synactpharma.com
Thomas Jonassen
CSO, SynAct Pharma AB
Phone: +45 40 15 66 69
Mail: tj@synactpharma.com
About SynAct Pharma AB
SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com.
